OIP5 and neoplasm: To examine the role of these pathways in tumor cell growth and metastatic ability, we measured cell growth in OIP5-expressing HLK3 cells treated with the mTORC1 inhibitor rapamycin (RPM, 100 nM) or the β-catenin inhibitor cardamonin (CDM, 10 μM).